Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cogent Biosciences (COGT)
NASDAQ:COGT
Holding COGT?
Track your performance easily
COGT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.67 - $12.14
Previous Close$10.55
Volume585.90K
Average Volume (3M)954.83K
Market Cap
$1.21B
Enterprise Value$809.67M
Total Cash (Recent Filing)$363.22M
Total Debt (Recent Filing)$18.18M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 11, 2024EPS Estimate
-$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.48
Shares Outstanding109,450,463
10 Day Avg. Volume782,160
30 Day Avg. Volume954,826
Standard Deviation0.67
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)4.45
Price to Sales (P/S)1212.02
Price to Cash Flow (P/CF)-6.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue852.28
Enterprise Value/Gross Profit852.28
Enterprise Value/Ebitda-3.54
Forecast
1Y Price Target
$16.67Price Target Upside50.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Cogent Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Independent Data Monitoring Committee recommended continuing the study without any changes after completing the interim futility analysis for the PEAK study.
Financial PositionCogent ended with $390 million in cash, which is still expected to fund operations into 2027.
Patient EnrollmentFull enrollment for the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis is now expected sooner due to high global patient demand.
Bears Say
Clinical DevelopmentSetbacks in later-stage clinical studies pose a significant risk.
Regulatory ApprovalsFailure to obtain regulatory approvals remains a critical concern.
Safety ProfileBezuclastinib's safety profile continues to look slightly worse than that of Ayvakit with issues like nausea, diarrhea, hair color changes, and taste disorder.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
COGT FAQ
What was Cogent Biosciences’s price range in the past 12 months?
Cogent Biosciences lowest stock price was $3.67 and its highest was $12.14 in the past 12 months.
What is Cogent Biosciences’s market cap?
Currently, no data Available
When is Cogent Biosciences’s upcoming earnings report date?
Cogent Biosciences’s upcoming earnings report date is Nov 11, 2024 which is in 52 days.
How were Cogent Biosciences’s earnings last quarter?
Cogent Biosciences released its earnings results on Aug 06, 2024. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.557 by -$0.033.
Is Cogent Biosciences overvalued?
According to Wall Street analysts Cogent Biosciences’s price is currently Undervalued.
Does Cogent Biosciences pay dividends?
Cogent Biosciences does not currently pay dividends.
What is Cogent Biosciences’s EPS estimate?
Cogent Biosciences’s EPS estimate is -$0.57.
How many shares outstanding does Cogent Biosciences have?
Cogent Biosciences has 109,450,460 shares outstanding.
What happened to Cogent Biosciences’s price movement after its last earnings report?
Cogent Biosciences reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.557. Following the earnings report the stock price went up 1.313%.
Which hedge fund is a major shareholder of Cogent Biosciences?
Among the largest hedge funds holding Cogent Biosciences’s share is Fairmount Funds Management Llc. It holds Cogent Biosciences’s shares valued at 52M.
---
Cogent Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (50.72% Upside)
$16.67 (50.72% Upside)
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.67%
12-Months-Change
Fundamentals
Return on Equity
-62.92%
Trailing 12-Months
Asset Growth
9.57%
Trailing 12-Months
Company Description
Cogent Biosciences
Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
---
COGT Stock 12 Month Forecast
Average Price Target
$16.67
▲(50.72% Upside)
Technical Analysis
Best Analysts Covering COGT
1 Year
1 Year Success Rate
6/10 ratings generated profit
1 Year Average Return
+21.04%
reiterated a buy rating 17 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +21.04% per trade.
---